References of "European Heart Journal"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailTreatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study
Linke, Axel; Wenaweser, Peter; Gerckens, Ulrich et al

in European Heart Journal (2014)

Aim Transcatheter aortic valve implantation has become an alternative to surgery in higher risk patients with symptomatic aortic stenosis. The aim of the ADVANCE study was to evaluate outcomes following ... [more ▼]

Aim Transcatheter aortic valve implantation has become an alternative to surgery in higher risk patients with symptomatic aortic stenosis. The aim of the ADVANCE study was to evaluate outcomes following implantation of a self-expanding transcatheter aortic valve system in a fully monitored, multi-centre ‘real-world’ patient population in highly experienced centres. Methods and results Patients with severe aortic stenosis at a higher surgical risk inwhomimplantation of theCoreValve Systemwas decided by the Heart Teamwere included. Endpointswere a composite of major adverse cardiovascular and cerebrovascular events (MACCE; all-cause mortality, myocardial infarction, stroke, or reintervention) and mortality at 30 days and 1 year. Endpoint- related eventswere independently adjudicated based on Valve AcademicResearch Consortiumdefinitions.Atotal of 1015 patients [mean logistic EuroSCORE 19.4+12.3% [median (Q1,Q3), 16.0% (10.3, 25.3%)], age 81+6 years] were enrolled. Implantation of the CoreValve System led to a significant improvement in haemodynamics and an increase in the effective aortic valve orifice area. At 30 days, theMACCErate was 8.0% (95% CI: 6.3–9.7%), all-cause mortalitywas 4.5% (3.2–5.8%), cardiovascular mortality was 3.4% (2.3–4.6%), and the rate of stroke was 3.0% (2.0–4.1%). The lifethreatening or disabling bleeding rate was 4.0% (2.8–6.3%). The 12-month rates of MACCE, all-cause mortality, cardiovascular mortality, and stroke were 21.2% (18.4–24.1%), 17.9% (15.2–20.5%), 11.7% (9.4–14.1%), and 4.5% (2.9–6.1%), respectively. The 12-month rates of all-cause mortality were 11.1, 16.5, and 23.6% among patients with a logistic Euro- SCORE ≤10%, EuroSCORE 10–20%, and EuroSCORE .20% (P , 0.05), respectively. Conclusion The ADVANCE study demonstrates the safety and effectiveness of the CoreValve System with low mortality and stroke rates in higher risk real-world patients with severe aortic stenosis. [less ▲]

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailRemote ischaemic pre-conditioning in cardiac surgery: benefit or not?
Kolh, Philippe ULg

in European heart journal (2014), 35(3), 141-3

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailThe appropriate and justified use of medical radiation in cardiovascular imaging: a position document of the ESC Associations of Cardiovascular Imaging, Percutaneous Cardiovascular Interventions and Electrophysiology.
Picano, Eugenio; Vano, Eliseo; Rehani, Madan M. et al

in European heart journal (2014), 35(10), 665-72

The benefits of cardiac imaging are immense, and modern medicine requires the extensive and versatile use of a variety of cardiac imaging techniques. Cardiologists are responsible for a large part of the ... [more ▼]

The benefits of cardiac imaging are immense, and modern medicine requires the extensive and versatile use of a variety of cardiac imaging techniques. Cardiologists are responsible for a large part of the radiation exposures every person gets per year from all medical sources. Therefore, they have a particular responsibility to avoid unjustified and non-optimized use of radiation, but sometimes are imperfectly aware of the radiological dose of the examination they prescribe or practice. This position paper aims to summarize the current knowledge on radiation effective doses (and risks) related to cardiac imaging procedures. We have reviewed the literature on radiation doses, which can range from the equivalent of 1-60 milliSievert (mSv) around a reference dose average of 15 mSv (corresponding to 750 chest X-rays) for a percutaneous coronary intervention, a cardiac radiofrequency ablation, a multidetector coronary angiography, or a myocardial perfusion imaging scintigraphy. We provide a European perspective on the best way to play an active role in implementing into clinical practice the key principle of radiation protection that: 'each patient should get the right imaging exam, at the right time, with the right radiation dose'. [less ▲]

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailCardiovascular imaging.
Lancellotti, Patrizio ULg; Habib, Gilbert; Negila, Danilo et al

in European heart journal (2014), 35(18), 1161-2

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailESC working group on valvular heart disease position paper-heart valve clinics: organization, structure, and experiences
LANCELLOTTI, Patrizio ULg; Rosenhek, R; Pibarot, P et al

in European Heart Journal (2013)

Detailed reference viewed: 53 (11 ULg)
Full Text
Peer Reviewed
See detailLeft ventricular contractile reserve in asymptomatic primary mitral regurgitation
Magne, Julien ULg; Mahjoub, H; PIERARD, Luc ULg et al

in European Heart Journal (2013)

Detailed reference viewed: 28 (6 ULg)
Full Text
Peer Reviewed
See detail2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
Montalescot, Gilles; Sechtem, Udo; Achenbach, Stephan et al

in European heart journal (2013), 34(38), 2949-3003

Detailed reference viewed: 169 (1 ULg)
Full Text
Peer Reviewed
See detailBenefit of revascularization for stable ischaemic heart disease: the jury is still out.
Fassa, Amir-Ali; Wijns, William; Kolh, Philippe ULg et al

in European heart journal (2013), 34(21), 1534-8

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
Steg, Ph Gabriel; James, Stefan K.; Atar, Dan et al

in European Heart Journal (2012), 33(20), 2569-619

Detailed reference viewed: 21 (4 ULg)
Full Text
Peer Reviewed
See detailESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
Reiner, Zeljko; Catapano, Alberico L; De Backer, Guy et al

in European Heart Journal (2011), 32(14), 1769-818

Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and ... [more ▼]

Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and is also increasingly common in developing countries.1 In the European Union, the economic cost of CVD represents annually E192 billion1 in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. Prevention and treatment of dyslipidaemias should always be considered within the broader framework of CVD prevention, which is addressed in guidelines of the Joint European Societies' Task forces on CVD prevention in clinical practice.2 - 5 The latest version of these guidelines was published in 20075; an update will become available in 2012. These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians [e.g. general practitioners (GPs) and cardiologists] interested in CVD prevention, but also specialists from lipid clinics or metabolic units who are dealing with dyslipidaemias that are more difficult to classify and treat. [less ▲]

Detailed reference viewed: 49 (0 ULg)